Literature DB >> 28392102

Creatine Phosphate Administration in Cell Energy Impairment Conditions: A Summary of Past and Present Research.

A V Gaddi1, P Galuppo2, J Yang3.   

Abstract

BACKGROUND: Creatine phosphate (CrP) plays a fundamental physiological role by providing chemical energy for cell viability and activity, especially in muscle tissue. Numerous pathological conditions, caused by acute or chronic ischaemic situations, are related to its deficiency. For these reasons, it has been used as a cardioprotective agent in heart surgery and medical cardiology for many years.
OBJECTIVE: This article gives a brief overview of the main characteristics of exogenous CrP.
METHODS: Previous review articles on CrP were screened for relevant information and references. Results from selected studies were reviewed and classified according to the topics in this review article and provided further interesting information on the pharmacological role of this molecule.
RESULTS: Besides CrP's well known cell energy and function restoring properties, new evidence is emerging regarding its antioxidant and anti-apoptotic properties. Use of CrP is well established clinically as an intraoperative and perioperative adjuvant in heart operations (valve replacement, coronary artery bypass grafting, congenital heart defect repair), and as an additional agent in medical cardiology therapy for acute myocardial infarction and acute and chronic heart failure. In particular, there are promising potential new CrP uses in neurology, such as in cerebral ischaemia and hypoxic ischaemic encephalopathy.
CONCLUSIONS: This review article describes the role of CrP treatment in cardiological indications, such as cardioprotection in cardioplegia and in myocardiopathies of various etiopathogenesis, as well as in other clinical indications such as skeletal muscle rehabilitation and neurological conditions.
Copyright © 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cardiac surgery; Cardioplegia; Cerebral ischaemia; Creatine phosphate; Heart failure; Myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 28392102     DOI: 10.1016/j.hlc.2016.12.020

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  6 in total

1.  Perspective: Creatine, a Conditionally Essential Nutrient: Building the Case.

Authors:  Sergej M Ostojic; Scott C Forbes
Journal:  Adv Nutr       Date:  2022-02-01       Impact factor: 11.567

2.  Left ventricular dysfunction after two hours of polarizing or depolarizing cardioplegic arrest in a porcine model.

Authors:  Terje Aass; Lodve Stangeland; Christian Arvei Moen; Atle Solholm; Geir Olav Dahle; David J Chambers; Malte Urban; Knut Nesheim; Rune Haaverstad; Knut Matre; Ketil Grong
Journal:  Perfusion       Date:  2018-07-30       Impact factor: 1.972

3.  Development of Triiodothyronine Polymeric Nanoparticles for Targeted Delivery in the Cardioprotection against Ischemic Insult.

Authors:  Ozlem Ozen Karakus; Noureldien H E Darwish; Thangirala Sudha; Taher A Salaheldin; Kazutoshi Fujioka; Peter C Taylor Dickinson; Brian Weil; Shaker A Mousa
Journal:  Biomedicines       Date:  2021-11-18

4.  Creatine Levels in Patients with Phenylketonuria and Mild Hyperphenylalaninemia: A Pilot Study.

Authors:  Elvira Verduci; Maria Teresa Carbone; Laura Fiori; Claudia Gualdi; Giuseppe Banderali; Claudia Carducci; Vincenzo Leuzzi; Giacomo Biasucci; Gian Vincenzo Zuccotti
Journal:  Life (Basel)       Date:  2021-05-06

5.  Self-Regulation of Cerebral Metabolism and Its Neuroprotective Effect After Hypoxic-Ischemic Injury: Evidence From 1H-MRS.

Authors:  Kexin Li; Yang Zheng; Xiaoming Wang
Journal:  Front Neuroanat       Date:  2021-06-17       Impact factor: 3.856

Review 6.  The creatine kinase system as a therapeutic target for myocardial ischaemia-reperfusion injury.

Authors:  Fang Cao; Sevasti Zervou; Craig A Lygate
Journal:  Biochem Soc Trans       Date:  2018-09-20       Impact factor: 5.407

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.